FindTrial
Sign In

European Randomized Study of Screening for Prostate Cancer.

European Randomized Study of Screening for Prostate Cancer.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29632
Enrollment
251133
Registered
2005-08-29
Start date
1991-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

PSA determination followed by DRE and prostate biopsy if PSA >= 3.

Sponsors

Prof. dr. F.H. Schröder Dept. Urology Erasmus MC P.O. Box 2040 3000 CA Rotterdam The Netherlands tel. +31-10-463 43 28 fax. +31-10-463 39 68 E-mail: e.vandenberg@erasmusmc.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Males aging 55-74 (including age 74).

Exclusion criteria

Exclusion criteria: Previous diagnosis of prostate cancer.

Design outcomes

Primary

MeasureTime frame
Prostate cancer mortality compared between the screened and the non-screened group of men at risk.—

Secondary

MeasureTime frame
1. Progression-free (tumor free) survival; 2. Survival free of metastatic disease; 3. Quality of life in the screened and non-screened populations.—

Contacts

Public ContactMonique Roobol-Bouts

Erasmus Medical Center, Department of Urology, P.O. Box 2040

m.roobol@erasmusmc.nl+ 31 (0)10 70 322 42

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)